GlassScriptPhysician profile
John Benson Welch
NPI 1356306534
$9,766.20
in general payments reported to CMS, 2019-2025
50 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,212 · 2020: $391 · 2021: $1,364 · 2022: $1,504 · 2023: $1,856 · 2024: $1,728 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,288 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,287.94 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,092.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,087.99 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,072.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,062.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.04 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Pfizer INC. | $432.06 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $358.26 | 2019-2025 | Rexulti |
| Amgen INC. | $332.70 | 2019-2024 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $305.54 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $293.30 | 2019-2025 | Eliquis, Camzyos |
| Lilly USA, LLC | $249.89 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Novartis Pharmaceuticals Corporation | $233.08 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $228.01 | 2019-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $212.58 | 2021-2025 | |
| Amarin Pharma, INC. | $179.25 | 2019-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $173.90 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $140.20 | 2020-2024 | Zoryve |
| Astellas Pharma US INC | $138.45 | 2021-2025 | Veozah |
| Sanofi Pasteur INC. | $124.18 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.80 | 2019-2023 | Trintellix |
| Lundbeck LLC | $112.20 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $107.21 | 2023 | Auvelity |
| Exact Sciences Corporation | $89.58 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $88.64 | 2019-2024 | Dificid |
| Genentech USA, INC. | $80.83 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $79.79 | 2022 | |
| Sumitomo Pharma America, INC. | $75.26 | 2024-2025 | Gemtesa |
| Cequr Corporation | $73.49 | 2024-2025 | Cequr Simplicity |
| Dexcom, INC. | $73.42 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.04 | 2021-2025 | Xifaxan |
| Daiichi Sankyo INC. | $59.79 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $58.45 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $53.22 | 2024 | Voquezna |
| Abbott Laboratories | $46.57 | 2021-2024 | Freestyle Libre 3 |
| Seqirus USA INC | $44.98 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Vanda Pharmaceuticals INC. | $31.03 | 2025 | Fanapt |
| Amneal Pharmaceuticals LLC | $28.74 | 2023 | Lyvispah |
| Biogen, INC. | $28.15 | 2024 | Leqembi |
| Clarus Therapeutics INC. | $23.29 | 2021 | |
| Ironshore Pharmaceuticals INC. | $22.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.40 | 2021 | |
| Viatris Specialty LLC | $16.76 | 2025 | Yupelri |
| Ultragenyx Pharmaceutical INC. | $16.74 | 2023 | Crysvita |
| Esperion Therapeutics, INC. | $15.72 | 2025 | Nexletol |
| Zealand Pharma US, INC. | $14.57 | 2021 | |
| Medtronic, INC. | $14.53 | 2023 | Inpen Smart Insulin Delivery System |
| Smith+Nephew, INC. | $14.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.89 | 2019 | |
| Tolmar, INC. | $13.08 | 2023 | |
| Avanir Pharmaceuticals, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.